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ABSTRACT
Objective: To assess the prevalence of somaticMTOR mutations in focal cortical dysplasia (FCD)
and of germline MTOR mutations in a broad range of epilepsies.
Methods: We collected 20 blood-brain paired samples from patients with FCD and searched for
somatic variants using deep-targeted gene panel sequencing. Germline mutations inMTOR were
assessed in a French research cohort of 93 probands with focal epilepsies and in a diagnostic
Danish cohort of 245 patients with a broad range of epilepsies. Data sharing among collaborators
allowed us to ascertain additional germline variants in MTOR.
Results: We detected recurrent somatic variants (p.Ser2215Phe, p.Ser2215Tyr, and
p.Leu1460Pro) in the MTOR gene in 37% of participants with FCD II and showed histologic
evidence for activation of the mTORC1 signaling cascade in brain tissue. We further identified
5 novel de novo germline missenseMTOR variants in 6 individuals with a variable phenotype from
focal, and less frequently generalized, epilepsies without brain malformations, to macrocephaly,
with or without moderate intellectual disability. In addition, an inherited variant was found in
a mother–daughter pair with nonlesional autosomal dominant nocturnal frontal lobe epilepsy.
Conclusions: Our data illustrate the increasingly important role of somatic mutations of theMTOR
gene in FCD and germline mutations in the pathogenesis of focal epilepsy syndromes with and
without brain malformation or macrocephaly. Neurol Genet 2016;2:e118; doi: 10.1212/
NXG.0000000000000118
GLOSSARY
ADHD 5 attention-deficit/hyperactivity disorder; ADNFLE 5 autosomal dominant nocturnal frontal lobe epilepsy; CADD 5
Combined Annotation Dependent Depletion; DEPDC5 5 Dishevelled, Egl-10, and Pleckstrin domain-containing protein 5;
DEPTOR 5 domain-containing mTOR-interacting protein; dPCR 5 digital PCR; ELM 5 eukaryotic linear motif; ExAC 5
Exome Aggregation Consortium; FAT 5 FRAP, ATM, TRRAP; FCD 5 focal cortical dysplasia; GATOR1 5 GTPase-activating
protein activity toward Rags complex 1; HEAT 5 huntingtin, elongation factor 3, protein phosphatase 2A, and TOR1; H&E 5
hematoxylin and eosin; mTOR 5 mammalian target of rapamycin; NPRL 5 nitrogen permease regulator–like.
A new class of genes encoding components of themechanistic target of the rapamycin (mTOR) signal
transduction pathway has recently been involved in familial focal epilepsies.1 Dishevelled, Egl-10, and
Pleckstrin domain-containing protein 5 (DEPDC5) together with nitrogen permease regulator–like
2 (NPRL2) and nitrogen permease regulator–like 3 (NPRL3) form the GTPase-activating
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protein activity toward Rags complex 1
(GATOR1), an amino acid–sensitive
inhibitor of mTORC1.2 Germline muta-
tions in the GATOR1-encoding genes
(DEPDC5, NPRL2, and NPRL3) have been
reported in numerous familial and sporadic
focal epilepsies.3–9 In addition to nonlesion-
al focal epilepsies, GATOR1 mutations
have also been recognized in epilepsies asso-
ciated with developmental cortical malfor-
mations such as focal cortical dysplasia
(FCD), in particular FCD type IIb (with
balloon cells) and IIa (without balloon
cells).10–14
Recent studies reported brain somatic
missense mutations in the MTOR gene itself
in 3 patients with hemimegalencephaly,12 in
12/77 (15%) with FCD II,15 in 6/13 (46%)
with FCD IIb,16 in 1 with FCD IIa,17 and in
10 with various developmental disorders
from FCD IIa to megalencephaly.18 Evi-
dence for mTORC1 hyperactivity was
shown in resected brain tissue after epilepsy
surgery.15,16,18
Rare germline heterozygous missense muta-
tions in MTOR have also been reported in
a subset of patients with megalencephaly,
intellectual disability, and seizures.18–22
In this study, we compared the prevalence
and type of MTOR somatic mutations in
a cohort of FCD patients, with MTOR germ-
line mutations in cohorts of patients with epi-
lepsy with or without brain malformations.
METHODS Patients. As a first step, 3 different cohorts were
screened for pathogenic variants in MTOR (figure 1).
First, for mosaic mutation detection, we prospectively re-
cruited a cohort of 20 participants with FCD who underwent
surgery to treat drug-resistant focal epilepsy. The cohort consisted
of 18 children operated at the Fondation Rothschild (Paris,
France) between 2015 and 2016 and 2 adult participants
Figure 1 Workflow of the study
FCD 5 focal cortical dysplasia; MCD 5 malformation of cortical development.
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operated at the Pitié-Salpêtrière hospital (Paris, France) and at the
Swiss Epilepsy Center (Zurich, Switzerland).
Second, for germline mutation detection, we included a previ-
ously described French research cohort of 93 unrelated European
patients with focal epilepsy, including 55 probands with familial
focal epilepsy, 9 sporadic patients with nonlesional focal epilepsy,
14 patients with familial focal epilepsy, and at least one family
member with FCD, and 15 sporadic patients with focal epilepsy
and FCD.8 In this cohort, 7 individuals were previously shown to
have a mutation in one of the GATOR1-encoding genes.8 We
also screened a third Danish cohort of 245 unrelated patients with
various forms of childhood-onset epilepsies referred for diagnostic
gene panel testing. The phenotypic spectrum within this cohort
was broad and ranged from benign familial neonatal/infantile
epilepsy to generalized epilepsies, focal epilepsies, and severe epi-
leptic encephalopathies.
In addition, we collected 5 previously unreported patients
with MTOR mutations through data sharing with Italy and the
United States. The Italian cohort consisted of 40 patients with
epilepsy, intellectual disability, and malformations of cortical
development or morphologic characteristics suggesting altered
neuronal proliferation. The US cohort consisted of 338 probands
(from 317 families) with developmental delay, intellectual disabil-
ity, and/or other neurologic symptoms, including epilepsy.
All probands and affected family members underwent
detailed clinical examination, including review of the medical
files, MRIs, and EEG investigations.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the following local ethical
committees: CPP Ile de France II, No ID-RCB/EUDRACT
2015-A00671-48, the Pediatric Ethical Committee of the
Tuscany Region, and the Institutional Review Board at the
University of Alabama at Birmingham (protocol #X130201001).
Written informed consent was obtained from each participant or
parents of minors. Parents of participants 10a, 10b, and 12 gave
consent for publication of their children’s picture. The Danish
cohort was recruited in a diagnostic setting, and the patients or
parents of minors gave written consent for publications of their
findings.
Genetic testing. Targeted gene panel for detection of somatic
variants. Genomic DNA was extracted from peripheral blood
lymphocytes and from fresh frozen resected brain tissue of
FCD participants. To search for mosaic mutations, we designed
a custom gene panel of 25 genes belonging to the PI3K/AKT/
mTOR pathway (SeqCapEZ custom design, Roche NimbleGen)
including MTOR and the GATOR1-encoding genes (DEPDC5,
NPRL2, and NPRL3).
Deep sequencing was performed on a NextSeq (2 3 75 nt).
GenoSplice performed quality control, processing, and detection
of the variants. FASTQ sequence files were mapped using hg19
reference with bwa-0.7.12 (mem) and converted to bam with
samtools-1-1. Single nucleotide variant and insertion/deletion
calling was performed with GATK-2014.3 to call heterozygous
germline variants present either in the resected brain or
lymphocyte-derived DNA.
Somatic variant calling was performed with samtools-1-1
(mpileup) to detect low frequency variants (i.e., ,10%). The
pileup was parsed with pileup2base which provides the count
of reads for each strand and nucleotides by coordinates. A
home-made Perl script was developed to filter variants according
to the following criteria: 1/variants not retrieved by GATK; 2/$
10 reads with the alternate allele; 3/$ 1% of allelic frequency;
and 4/maximum strand bias value of 0.5.
Picoliter droplet-based digital PCR. Somatic p.Ser2215Phe
and p.Ser2215Tyr mutations were confirmed by digital PCR
(dPCR). Genomic DNA was extracted from a second piece of
the same tissue block from participants 1–5 and was tested for
the presence of specific MTOR mutations. No brain tissue of
patient 6 was left. Custom LNA double-dye probes designed to
detect both mutant alleles c.6644C.T (p.Ser2215Phe) and
c.6644C.A (p.Ser2215Tyr) and wild-type were purchased from
Eurogentec. RainDrop Digital PCR system (Raindance Tech-
nologies Billerica) was used as previously described23 with the
following modifications: dPCR was performed with Taqman
Universal Master Mix (life Technologies), 125 nM final con-
centration of both probes and 250 nM final concentration of
primers.
Targeted gene panels for detection of germline variants. In
the French cohort of 93 patients with focal epilepsies, the search
for heterozygous variants in genomic blood DNA was accom-
plished by a previously reported methodology and research epi-
lepsy panel consisting of 76 genes (SeqCapEZ custom design,
Roche NimbleGen).8
In the Danish cohort, the genomic blood DNA from 245 pa-
tients with various childhood-onset epilepsies was screened using
a diagnostic sequencing panel (Sure Select, Agilent Technologies)
consisting of 85 epilepsy genes.
The Italian cohort of 40 patients was screened using a gene panel
consisting of 15 genes belonging to the PI3K/AKT/mTOR pathway
(HaloPlex Target Enrichment System, Agilent Technologies).
MTOR variants were assumed to be pathogenic if they were
nonsynonymous missense, seen less than 2 times in control sam-
ples (Exome Aggregation Consortium (ExAC) set of ;61,000
exomes—exac.broadinstitute.org [accessed August 2016]), had
arisen de novo in patients without family history of epilepsy, or
segregated with the disease in the family. Sanger sequencing was
used to confirm all variants.
Exome/genome sequencing for detection of germline
variants. The 338 USA probands were subject to trio-based
exome or genome sequencing as part of a Clinical Sequencing
Exploratory Research project (conducted at the HudsonAlpha
Institute for Biotechnology).24 Whole-exome (patients 10a, 10b,
and 11) or genome (patient 12) sequencing was conducted to
a median depth of 65X or 30X, respectively. Exome capture was
completed using NimbleGen SeqCapEZ Exome version 3. Reads
were aligned to reference hg19 using bwa (0.6.2). GATK best
practice methods were used to identify variants. Maternity and
paternity of each parent were confirmed by whole-exome/genome
kinship coefficient estimation with KING. De novo variants were
identified as heterozygous variant calls in the proband in which
there were at least 10 reads in both parents and the proband, an
alternate allele depth of at least 20% in the proband and less than
5% in each parent, and a minor allele frequency ,1% in the
1000 Genomes Project and the ExAC. All candidate de novo
variants that either affected a protein or had a scaled Combined
Annotation Dependent Depletion (CADD) score .10 were
manually reviewed.25 In each patient described, no other variants
were identified as potentially disease causing. All de novo variants
were confirmed by Sanger sequencing to be heterozygous in the
probands and absent from both of their parents.
Histopathology and immunostaining. Histopathologic diag-
nosis was made according to the classification of the International
League Against Epilepsy Diagnostic Methods Commission26 and
included 3 FCD I, 9 FCD IIa, 7 FCD IIb, and 1 FCD III. Paraffin-
embedded resected brain tissues of patients 1–5 were examined for
the presence of cytoarchitectural features of FCD using
hematoxylin and eosin (H&E) staining. Brain tissue of patient 6
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was not available for further immunostaining. mTORC1 activity
was assessed by visualizing the phosphorylation level of its
downstream effector, the ribosomal protein S6, a commonly used
biomarker in mTORC1 pathway research.27 Sections (10 mm)
were probed overnight at 4°C with an antibody against Ser235/
236 phosphorylated S6 (#4856, 1:200 dilution; Cell Signaling,
Danvers, MA) and visualized using avidin-biotin conjugation
(Vectastain ABC Elite; Vector Laboratories, Burlingame, CA).
Images were acquired using the Leica DM2500 microscope.
Protein modeling. Protein modeling was performed using
YASARA structure (yasara.org), merging 29 models of multiple
PDB files. Molecular dynamic simulations were performed using
AMBER031, and structure statistics were calculated with the
YASARA2 z score calculation. Eukaryotic linear motif (ELM)
predictions were performed on the ELM server 3, and
posttranslational modifications were predicted using multiple
prediction tools.28–36
RESULTS Brain somatic mutations in MTOR. To
identify low-level mosaic mutations, we designed
a targeted sequencing panel comprising all 57
coding exons and flanking intronic regions of
MTOR (NM_004958.3) and the GATOR1-
complex encoding genes (DEPDC5, NPRL2, and
NPRL3). We achieved a high sequencing coverage of
all 4 genes (mean coverage: 2,6533, 2,5273,
2,6663, and 2,3423, respectively). We searched for
mosaic variants with allele frequencies $1%. We
detected neither germline nor mosaic coding
pathogenic variants in DEPDC5, NPRL2, or NPRL3
according to our filtering criteria. Brain mosaic
mutations in MTOR were found in 2 patients with
FCD IIa and 4 patients with FCD IIb (table 1, figure
1), representing 37% (6/16) of all FCD II individuals.
A recurrent variant in MTOR (c.6644C.T/p.
Ser2215Phe) was identified in patients 1–3 in 138/
2,186 (6.31%), 79/2,504 (3.15%), and 28/2,481
(1.13%) reads, respectively. A second recurrent
variant (c.6644C.A/p.Ser2215Tyr) affecting the
same nucleotide was detected in patients 4–5 in 26/
718 (3.62%) and 12/751 (1.6%) reads. Patient 6 with
FCD IIb carried 2 MTOR variants located on the
same allele: the recurrent variant c.4379T.C/p.
Leu1460Pro was detected in 62/2,522 (2.46%)
reads and c.4375G.T/p.Ala1459Ser (never
reported) was detected in 60/2,493 (2.41%) alleles.
To validate these findings, we performed picoliter
droplet-based dPCR based on the single-molecule
parallel amplification of MTOR wild-type and
mutated alleles. dPCR confirmed both the presence
and the allelic frequencies of the 2 c.6644C.T/p.
Ser2215Phe and c.6644C.A/p.Ser2215Tyr variants
in DNA sample replicates from the same tissue block
to exclude sequencing artifacts (table 1).
Table 1 Clinical features of patients with somatic MTOR variants in FCD
Participant (origin) Patient 1 (French) Patient 2 (French) Patient 3 (French) Patient 4 (French) Patient 5 (French) Patient 6 (French)
Sex/age, y F/15 M/15 M/2 M/7 M/1 M/28
Variants: c.DNA/
protein
c.6644C.T/
p.Ser2215Phe
c.6644C.T/
p.Ser2215Phe
c.6644C.T/
p.Ser2215Phe
c.6644C.A/
p.Ser2215Tyr
c.6644C.A/
p.Ser2215Tyr
c.4379T.C/
p.Leu1460Pro
c.4375G.T/
p.Ala1459Ser
Allele frequency in
brain tissue: panel/
digital PCR, %
6.31/6.8 3.15/2.62 1.13/0.93 3.62/3.67 1.6/1.06 2.46/not done; 2.41/not
done
Allele frequency in
blood, %
3.16 1.45 0.63 0.13 0.82 1.30
Age at onset 18 mo 16 mo 2 mo 2 mo 2 mo 6 y
Seizure types Left head deviation
then atonic and
tonic seizures
Eye deviation, then
head sensation,
and right hand
dystonia
Clonic sz,
infantile spasms
Asymmetric infantile
spasms, then clonic
eye movements
Asymmetric infantile
spasms, clonic eye
movements
Drop attacks, nocturnal
sz with psychic aura,
loss of consciousness,
gestural automatisms
EEG Left fronto-parietal
focus and sz
Left basal frontal
focus and sz
Left anterior
temporal focus
and sz
Multifocal right
frontal and parietal
Posterior right
multiple foci
Right middle and
posterior temporal
discharges
MRI findings (age
at investigation)
Left frontal FCD
(3 y)
Left frontal FCD
(18 mo)
Left anterior
temporal FCD
(23 mo)
Right parieto-
occipital FCD
(12 mo)
Right temporo-
occipital FCD
(9 mo)
Right posterior temporal
FCD (23 y)
Histology FCD IIb FCD IIb FCD IIa, with few
balloon-like cells
FCD IIb FCD IIa FCD IIb
Cognition Mild ID Mild ID Mild ID Normal Mild ID Memory impairment
Neurologic
examination
Normal Attention deficit Attention deficit and
motor hyperactivity
Normal Left strabismus Normal
Postoperative
outcome
Engel 1a at 8 mo Engel 1 during
7 mo after
surgery, then
Engel 3
Engel 2 at 6 mo Engel 1 during 4 mo
after surgery, then
Engel 3
Engel 1 at 10 mo Engel 1b at 2 y
Abbreviations: FCD 5 focal cortical dysplasia; ID 5 intellectual disability; sz 5 seizures.
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All recurrent mosaicMTOR variants were predicted
deleterious by SIFT, disease-causing by Mutation
Taster, and possibly damaging by PolyPhen-2, and
were absent from the ExAC database. Allele frequen-
cies of the mosaic variants were low in the genomic
DNA extracted from the brain tissues (range
1.1%–6.3%) (table 1). We noticed that with the high
sensitivity of the deep sequencing, mosaic variants
could also be detected in the blood DNA, although
with allele frequencies half lower than in the brain
DNA (range 0.1%–3%). However, these variants were
not present in the blood DNA of patients without
detected MTOR brain somatic mutations. The recur-
rent variants p.Ser2215Phe, p.Ser2215Tyr, and p.
Leu1460Pro were considered to be pathogenic as they
have already been linked to FCD.15,16,18 These mosaic
variants were detected across several studies using dis-
tinct technologies and sequencing platforms, excluding
that they might correspond to sequencing artifacts.
Germline mutations in MTOR. In the French cohort of
93 patients with focal epilepsy, we identified only one
germline variant (c.4128T.G/p.Asp1376Glu) in
a patient with nonlesional focal epilepsy with auditory
features. This novel variant was predicted deleterious
by all in silico prediction tools and was absent from
the ExAC database. Sanger sequencing, however, re-
vealed that the variant was inherited from the asymp-
tomatic father and was thus considered to be a variant
of unknown significance.
In the Danish cohort consisting of 245 patients, we
detected 2 germline heterozygous variants in MTOR
(c.5494G.A/p.Ala1832Thr and c.7501A.G/p.
Ile2501Val) corresponding to ;1% of a diagnostic
cohort of patients with childhood-onset epilepsy (fig-
ure 1, table 2). Variant c.5494G.A/p.Ala1832Thr
occurred de novo in patient 7 with nonlesional occip-
ital lobe epilepsy, macrocephaly, learning difficulties,
and attention-deficit/hyperactivity disorder (ADHD).
Based on the de novo occurrence, highly evolutionary
conservation of the Ala1832 amino acid, and low fre-
quency in the ExAC database (1/110,816 chromo-
somes), we considered the p.Ala1832Thr variant to
be pathogenic. The c.7501A.G/p.Ile2501Val vari-
ant, identified in patient 8a, also affects a highly evo-
lutionary conserved amino acid, was predicted to be
disease causing by Mutation Taster (but was predicted
to be benign by SIFT and PolyPhen-2) and was absent
in the ;61,000 individuals from the ExAC database.
The p.Ile2501Val variant was inherited from an
affected mother (patient 8b). Both proband and
mother had nonlesional nocturnal frontal lobe epi-
lepsy, a phenotype compatible with autosomal domi-
nant nocturnal frontal lobe epilepsy (ADNFLE).
Patients 7 and 8a did not carry additional pathogenic
variants in one of the 84 epilepsy genes of the panel,
including genes known to be involved in ADNFLE
such as CHRNA4, CHRNA2, CHRNB2, DEPDC5,
or KCNT1, suggesting that this variant is likely to be
pathogenic.
Further germline MTOR mutations were identi-
fied through data sharing with collaborators in the
United States and Italy. We collected 4 additional
de novo germline MTOR mutations as follows:
c.4468T.C/p. p.Trp1490Arg (patient 9, Italian
cohort); c.5663A.C/p.Phe1888Cys (identical
twin pair, patients 10a and 10b, USA cohort);
c.4785C.T/p.Met1595Ile (patient 11, USA
cohort); and c.6981G.A/p.Met2327Ile (patient
12, USA cohort) (figure 1, table 2). All six variants
were predicted to be disease-causing by different in
silico prediction methods and were absent from the
ExAC database. Sanger confirmation and segregation
analysis revealed that all variants occurred de novo,
suggesting that they are likely to be pathogenic.
Prediction of pathogenicity. We assessed the deleteri-
ousness of the MTOR variants using different predic-
tion tools. First, we calculated the CADD scores for
all novel germline variants: 15.18 (p.Ile2501Val),
19.76 (p.Ala1832Thr), 26 (p.Met1595Ile), 29.2
(p.Phe1888Cys), and 34 (p.Met2327Ile), as well
as the somatic variants: 26.1 (p.Leu1460Pro),
31 (p.Ala1459Ser), 32 (p.Ser2215Tyr), and 33
(p.Ser2215Phe). CADD scores were clearly consis-
tent with them being pathogenic.
Second, we observed in ExAC that the number of
missense variants expected in MTOR is 930, while
those observed are only 438 (z score 5 7.89), indi-
cating that MTOR is intolerant to missense variants.
For each variant identified in each cohort, we per-
formed a x2 test with Yates correction (graphpad.
com/quickcalcs/contingency1.cfm) using the
;61,000 ExAC individuals as a control cohort. All
MTOR variants, either novel germline or recurrent
somatic, reached extremely statistically significant val-
ues (p, 0.0001). In addition, with a 0.34% Residual
Variation Intolerance Score (RVIS), MTOR ranks
among the top most constrained human genes.37
Furthermore, we asked how the variants may affect
the structure and/or function of the mTOR protein.
Structural domains are composed of 2 HEAT (hun-
tingtin, elongation factor 3, protein phosphatase 2A,
and TOR1) domains, the FAT (FRAP, ATM,
TRRAP) domain, the FKBP12-rapamycin binding
domain, the kinase domain, and the FAT C-terminal
domain. Most mutations reported here, either somatic
or germline, were clustered in and around the FAT
and the kinase domains (figure 2). The crystal struc-
ture of mTOR has revealed that the FAT domain
interacts with the kinase domain38 and DEP
domain-containing mTOR-interacting protein
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Table 2 Clinical features of patients with germline MTOR variants
Participant
(origin)
Patient 7
(Danish)
Patient 8a
(Danish)
Patient 8b
(Danish)
Patient 9
(Italian)
Patient 10a
(USA)
Patient 10b
(USA)
Patient 11
(USA)
Patient 12
(USA)
Sex/age, y F/8 F/44 F/70 M/6 F/23 F/23 M/8 F/2.5
Variant:
c.DNA/protein
c.5494G.A/
p.Ala1832Thr
c.7501A.G/
p.Ile2501Val
c.7501A.G/
p.Ile2501Val
c.4468T.C/
p.Trp1490Arg
c.5663A.C/
p.Phe1888Cys
c.5663A.C/
p.Phe1888Cys
c.4785C.T/
p.Met1595Ile
c.6981G.A/
p.Met2327Ile
Inheritance Germline de
novo
Germline
maternal
Transmitted to
daughter
Germline de
novo
Germline de novo Germline de novo Germline de
novo
Germline de
novo
Family history
of seizures
FS (father and
sister)
Focal epilepsy
(mother)
Focal epilepsy
(daughter)
None Identical twin
sister same
phenotype
Identical twin
sister same
phenotype
None None
Age at seizure
onset
Diagnosis at
2 y 3 mo.
Retrospectively,
onset at 8 mo
2 y Diagnosis at 28 y.
Retrospectively,
onset in childhood
(age 10 y)
2 y 5 mo 4 y 6 y 12 mo No seizures
Seizure
description
Irresponsive,
cyanosis,
generalized
stiffening; visual
aura, sensation
of vomiting,
irresponsive,
elevation of
the eyes
Nocturnal
focal seizures;
rising sensory
aura,
generalized
stiffening with
preserved
consciousness;
precipitated
by fever
TCS, two episodes
of convulsive SE,
nocturnal focal
seizures: rising
sensory aura,
generalized
stiffening with
preserved
consciousness;
precipitated by
fever (also during
wakefulness)
Focal motor
seizures with
rhythmic jerks
of left arm, leg,
and face, often
during sleep
Irresponsive
preceded or
followed by
detached
laughing; TCS;
convulsive status
epilepticus
Giddy laughing
with
hyperactivity;
TCS; convulsive
status epilepticus
(age 8)
Myoclonic;
generalized
TCS
No seizures
EEG Right occipito-
parietal spikes
and slow
activity
Theta activity
intermixed
with normal
background
activity
Polyspike wave
with left-side
predominance and
slow wave activity
with left temporal
predominance
Slow and sharp
waves during
sleep, both
diffuse and
focal, mainly
involving right
hemisphere
Persistent diffuse
sharp and slow
wave activity,
most prominent
over right
hemisphere
Mild slow
background,
diffuse and left
centro-temporal
epileptiform
discharges
Irregular
slowing of
background
rhythms and
frequent bursts
of generalized
1–2 Hz SWC
Normal
Epilepsy
syndrome
Focal epilepsy,
occipital lobe
Focal epilepsy,
nocturnal
frontal lobe
Focal epilepsy,
nocturnal frontal
lobe
Focal epilepsy,
probably
fronto-
temporal lobe
Focal epilepsy,
probably frontal or
temporal lobe
Focal epilepsy,
probably frontal
or temporal lobe
Generalized
epilepsy
No epilepsy
MRI findings Aspecific
bifrontal white
matter signal
changes at 3 y
(1.5T)
Incomplete
inversion of left
hippocampus;
pineal gland
cyst;
arachnoidal
cyst at 42 y
(1.5T)
Normal (1.5T) Thin corpus
callosum,
ventricular
dilatation at 2
y 8 mo and 5 y
(3T)
Ventricular
prominence with
mild extra
ventricular
enlargement
at 6 mo (1.5T)
Mild ventricular
prominence at
6 mo (1.5T)
Normal at 18
mo
Mild
ventricular
dilatation and
increased
extra-axial
spaces at 20
mo (1.5T)
Cognition
before sz
onset
Not available Normal Normal Mild delay Delayed Delayed Delayed Delayed,
moderate ID,
behavioral
outbursts
Cognition and
behavior after
sz onset
Learning
difficulties,
ADHD
Anxiety Normal Mild ID (IQ 64) Moderate ID,
aerophagia,
autism
Moderate ID,
autism
Moderate ID,
autism
Not applicable
Neurologic
examination
Normal Normal Normal Normal Hypotonia,
nonverbal,
shuffling gait
Hypotonia,
nonverbal,
shuffling gait
Ataxic gait,
hypotonia
Normal
Treatment
response
Drug resistant LEV effective
(seizures only
with fever)
Seizure-free since
age 36 y, on CBZ
CBZ effective;
last seizure at
4 y 7 mo
No response to
VPA; good
response to TPM
Partial response
to LEV, good
response to TPM
TPM and VPA
side effects,
currently LEV,
ZNS, and CLB
Not applicable
Dysmorphic
features,
including HC
Macrocephaly:
HC 56 cm at
8 y (13.31 SD);
no dysmorphic
features
HC 54.2 cm
at 44 y (20.11
SD); no
dysmorphic
features
HC 56 cm at last
follow-up (11.52
SD); no
dysmorphic
features
Macrocephaly:
HC 54 cm at 3
y (12.8 SD); no
dysmorphic
features
Macrocephaly: HC
61.3 cm at 12 y
(15.8 SD). Facial
dysmorphy:
prominent
forehead, low-set
ears, gingival
hyperplasia,
frontal bossing,
kyphosis,
micrognathia, long
thin extremities
Macrocephaly:
HC 60 cm at 12 y
(14.9 SD). Facial
dysmorphy:
prominent
forehead, low-set
ears, gingival
hyperplasia,
frontal bossing,
kyphosis,
micrognathia; long
thin extremities
HC 49 cm at 18
mo (10.95 SD);
dysmorphology
not done
Macrocephaly:
HC 52.3 cm at
20 mo (14.1
SD). Facial
dysmorphy:
frontal
bossing, broad
depressed
nasal root,
coarse facial
features
Abbreviations: ADHD 5 attention-deficit/hyperactivity disorder; CBZ 5 carbamazepine; CLB 5 clobazam; FS 5 febrile seizures; HC 5 head circumference;
ID 5 intellectual disability; LEV 5 levetiracetam; SWC 5 spike-and-wave complexes; TCS 5 tonic-clonic seizures; TPM 5 topiramate; VPA 5 valproic acid;
ZNS 5 zonisamide.
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(DEPTOR),39 a repressor of mTOR activity. We can
speculate that mutations in the FAT domain may alter
the conformational structure of protein or inhibit the
binding with DEPTOR, maintaining the catalytic site
exposed and active.
We further performed protein modeling of
mTOR and showed that most of the variants seen have
a high probability of altering protein structure and
dynamics through either altered hydrophobic collapse
(p.Met1595Ile, p.Met2327Ile, and p.Ile2501Val),
helical packing (p.Ala1459Ser, p.Leu1460Pro, and
p.Ser2215Phe/Tyr), or surface conserved sites likely
involved in protein-protein interactions (p.Trp1490Arg)
(table e-1, figure e-1 at Neurology.org/ng).While amino
acid 1888 is not as strongly conserved, Phe1888Cys is
predicted to elevate the probability for protein lipidation
(myristoylation, palmitoylation, and farnesylation),
a modification known to alter protein localization, and
thus is also likely to deleteriously impact mTOR func-
tion. Altogether, these missense variants in MTOR are
likely to be pathogenic.
Phenotypic analysis. Brain mosaic mutations in
MTOR were found in 2 patients with FCD IIa and
in 4 with FCD IIb (table 1), representing 37% (6/
16) of all FCD II individuals. No MTOR variants
were found in the 3 patients with FCD I nor in the
only patient with FCD III. All patients had charac-
teristic imaging features of FCD (figure 3) and drug-
resistant focal epilepsy prior to surgery. Postoperative
outcome ranged from Engel class 1 to 3.
Histopathology of resected brain tissue showed an
FCD IIa with dysmorphic neurons on H&E
staining in patients 3 and 5, and an FCD IIb with
dysmorphic neurons and balloon cells in patients 1,
2, and 4 (figure 3). We assessed mTORC1 activity
by visualizing the phosphorylation level of its
downstream effector S6 on Ser235/236 (pS6),
a well-recognized marker of mTORC1 activity.27
Hyperactivation of the mTORC1 pathway as
shown by S6 intense phosphorylation was observed
in dysmorphic neurons of patients with FCD IIa and
FCD IIb, in contrast to apparently normal adjacent
neurons.
Germline mutations were found in patients with
a variable phenotypic spectrum (table 2). Seven of
the 8 individuals with germline variants had epilepsy.
Six had focal epilepsy, and 1 had generalized epi-
lepsy, with age at onset ranging from 8 months to
6 years. The presumptive lobe of seizure onset was
variable from frontal, fronto-temporal to occipital.
One mother–daughter pair (patients 8a and 8b)
had ADNFLE, and 2 patients formed an identical
twin pair (patients 10a and 10b) with gelastic seiz-
ures. Four patients did not have a family history of
epilepsy. Five patients had macrocephaly, and 3 had
dysmorphic facial features (figure 4). All patients
with germline mutations had either normal imaging
or unspecific MRI abnormalities including thin cor-
pus callosum and/or ventricular dilatation (figure 4).
Three patients had a normal or near normal devel-
opment, 1 patient had mild and 4 had moderate
intellectual disability. Behavioral and psychiatric dis-
turbances including autistic features and ADHD
were reported in 4 patients. No specific dermatolog-
ical features were observed.
DISCUSSION Brain somatic MTOR mutations have
recently been identified in patients with malforma-
tions of cortical development, in particular FCD (for
review reference 40). In this study, we report recur-
rent somatic mutations in MTOR in 30% of patients
with FCD and 37% of patients considering only pa-
tients with FCD II (2 FCD IIa and 4 FCD IIb). We
also describe 8 patients with a spectrum of develop-
mental disorders due to germline MTOR mutations.
While most patients had focal (and less frequently
generalized) epilepsy, mild-to-moderate intellectual
Figure 2 Domain/structural organization of mTOR protein with the positions of the mutations indicated
In black: germline mutations; in blue: somatic mutations; in bold: recurrent mutations. Structural domains are composed of HEAT (huntingtin, elongation fac-
tor 3, protein phosphatase 2A, and TOR1) repeats; FAT (FRAP, ATM, TRRAP) domain; FRB (FKBP12-rapamycin binding) domain; kinase domain; and FATC
(FAT C-terminal) domain.
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Figure 3 Imaging, histopathology, and mTORC1 pathway activity of patients with focal cortical dysplasia
(A) MRI with residual lesion after the first and before the second operation because of incomplete initial resection (preop-
erative MRI unavailable). (D, G, J, M, P) Preoperative brain MRI; arrows indicate the dysplastic lesion. (B, E, H, K, N) Hematox-
ylin and eosin (H&E) staining; blue arrows indicate balloon cells, and black arrows indicate dysmorphic neurons. (C, F, I, L, O)
Ser235/236 phosphorylated S6 (pS6 235/6) immunostaining counterstained with hematoxylin, showing labeling of dys-
morphic neurons. Brain tissue of patient 6 was not available for further immunostaining. Scale bar: 20 mm. FCD 5 focal
cortical dysplasia.
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disability, and/or dysmorphic features, we extended
the phenotypic spectrum associated with germline
variants to milder phenotypes than previously
reported; none of the patients had a malformation
of cortical development identified on MRI, and 3
patients had (near) normal cognitive outcome. At
the mildest end of the spectrum, 1 mother–
daughter pair had nonlesional treatment-responsive
ADNFLE and normal intellectual development. In
addition, we report 1 individual with macrocephaly
and intellectual disability without seizures. Our
results are consistent with previous studies reporting
individuals with megalencephaly and seizures due to
germline activating mutations in MTOR.18–22
In a previous report, the level of mosaicism of
somatic mutations has been suggested to correlate
with the extent of the brain malformation.18 In our
series of patients with FCD, we could not directly
correlate the allele frequencies of somatic variants to
the size of the lesion. Given the central and ubiqui-
tous role of the mTORC1 transduction pathway in
regulating cell functions, it was surprising to discover
heterozygous germline MTOR mutations in the fol-
lowing: (1) patients with purely neurologic symptoms
and (2) patients without brain malformations, in con-
trast to individuals with somatic mutations. Two pos-
sible hypotheses can be raised. First, it appears that
the amino acids affected by germline mutations are
different from the ones affected by somatic muta-
tions. All variants were missense, assumed to enhance
the activity of the mTORC1 pathway. However,
while somatic mutations may be hyperactivating,
and thus cause brain malformations of development,
germline mutations could be less activating. A second
hypothesis is the possible occurrence during brain
development of multiple-hit mosaic mutations
(missed with our targeted sequencing strategy) in dif-
ferent genes of the same pathway, explaining the
apparition of a focal lesion as seen in FCD. This
scenario is known as the multiple-hit or Knudson
hypothesis in cancer41 and is supported by our pre-
vious report of a patient with FCD with both
a somatic and a germline DEPDC5 mutation.11 It is
also supported by the finding that brain somatic mu-
tations occur frequently.42 In this FCD cohort, we
did not identify an MTOR or a GATOR1 germline
mutation in addition to the somatic MTOR variants.
While the somatic MTOR mutations were recur-
rent, all germline mutations identified in this study were
novel. Recurrence of p.Ser2215Phe, p.Ser2215Tyr, and
p.Leu1460Pro mutations that result in mTOR activa-
tion in multiple FCD cases15,16,18 suggests mutational
hotspots. Of interest, the same recurrent mutations
were also found in various tumors (cancer.sanger.ac.
uk/cancergenome/projects/cosmic).43 Most of these
oncogenic mutations, like FCD-causing mutations,
cluster near the kinase domain and the FAT domain
of mTOR protein. A recent study reported that
the hyperactive kinase domain p.Met2327Ile variant
confers drug resistance to mTOR second-generation
inhibitors suggesting potential issues in the field of
precision medicine.44
The role of genes of the GATOR1-mTORC1
pathway (MTOR, DEPDC5, NPRL2, and NPRL3)
is being increasingly recognized in focal epilepsies,
with and without structural abnormalities.1 Most mu-
tations in GATOR1-encoding genes are loss of func-
tion (nonsense, frameshift, splice variants), while all
mutations in theMTOR gene are missense mutations
predicted to be activating. Both GATOR18,13,14 and
MTOR mutations17 have been shown to lead to hy-
peractivation of the mTORC1 pathway in resected
Figure 4 Unspecific MRI findings and facial dysmorphy in patients with
germline variants
(A and B) T2-weighted3TMRI images of patient 9. Axial image shows dilated lateral ventricles
(A), and sagittal image shows thinning of the posterior half of the corpus callosum (B). (C andD)
Pictures of identical twin pair 10a and 10b show prominent forehead, low-set ears, gingival
hyperplasia, frontal bossing, and micrognathia (MRIs not available for publication). (E–G)
Fluid-attenuated inversion recovery (FLAIR) weighted 1.5T MRIs of the brain, and the picture
of patient 12. Axial and coronal images shows mild ventricular dilatation. Picture shows
macrocephaly with frontal bossing, broad depressed nasal root, and coarse facial features.
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epileptogenic brain tissue. How an increased activity
of the intracellular signaling cascade alters network
function and ultimately leads to seizures is one of
the next challenging questions to be elucidated.
This study confirms the important role of somatic
MTOR mutations in the pathogenesis of FCD, and
jointly with previous reports shows that germline
MTOR mutations may contribute to a broad pheno-
typic spectrum, ranging from focal epilepsy without
MRI-detectable brain abnormalities and normal devel-
opment, to hemimegalencephaly, intellectual disabil-
ity, and epilepsy. The treatment effectiveness in these
patients with mTORC1 pathway inhibitors needs fur-
ther evaluation, but meanwhile, screening ofMTOR in
a broad range of focal epilepsies is warranted.
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